The current state of the market seems to have frozen the wallets of some big-named VC firms that went big last year. In November 2021, Tiger Global made 25 deals. Last month that number dropped to five.

Similarly, General Catalyst took part in 19 funding rounds in November of last year. The VC giant took part in only a half-dozen last month.

The lack of firms doing a few dozen in a month allowed a couple accelerators — Techstars Workforce Development Accelerator and Y Combinator — to claim two of the top four spots.

One of the startups included in the latest batch announced early last month was Skylyte, which provides burnout awareness and burnout training to help keep employees happy and healthy. The company — which thinks of itself as a “digital chief wellness officer” — uses data to track behavior changes and mood trends to follow team health. While obviously benefiting their employee, it also can benefit the company by cutting down on employee churn and increasing productivity.

Gaingels, 13 deals

Gaingels makes it back to this list after a month away. One of its baker’s dozen of investments last month included a pretty big $20 million seed round for Seattle-based aerospace startup Gravitics.

However, the company isn’t just any aerospace startup — it develops space station modules. Its StarMax module provides up to 400 cubic meters of habitable volume. That is nearly half the volume of the International Space Station in just one StarMax module. The modules are also compatible to launch on any of the several vehicles now rocketing to space.

Hawaii-based Elemental Excelerator and New York-based BoxGroup came in next on the list with eight and seven deals, respectively.

Techstars Workforce Development Accelerator led or co-led the most rounds in November with 13. Andreessen Horowitz came in next with nine rounds led or co-led.

Bain Capital Life Sciences led or co-led rounds totaling the most dollars for the month. The firm led or co-led two rounds that totaled nearly $400 million — including biotech startup Emalex Biosciences’ $250 million Series D.